Donepezil in vascular dementia: a randomized, placebo-controlled study

Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J, Kertesz, A. and Pratt, R.D., Donepezil 308 Study Group Donepezil 308 Study Group (2003) Donepezil in vascular dementia: a randomized, placebo-controlled study Neurology, 61, (4), pp. 479-486.


[img] PDF 00006114-200308260-00013.pdf - Version of Record
Restricted to Repository staff only

Download (175kB)


Objective: To evaluate the efficacy and tolerability of donepezil in patients with vascular dementia (VaD).
Methods: Patients (n = 616; mean age, 75.0 years) with probable or possible VaD, according to National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche en l’Enseignement en Neurosciences criteria, were randomized to receive donepezil 5 mg/day (n = 208), donepezil 10 mg/day (after 5 mg/day for the first 28 days) (n = 215), or placebo (n = 193) for 24 weeks.
Results: Seventy-six percent of the patients enrolled had probable VaD. A total of 75.3% of the 10 mg donepezil group and 80.8% of the 5 mg group completed the study compared with 83.4% of the placebo group. Both donepezil-treated groups showed improvements in cognitive function on the Alzheimer’s Disease Assessment Scale–cognitive subscale compared with placebo, with a mean endpoint treatment difference, as measured by the change from baseline score, of approximately 2 points (donepezil 5 mg, -1.65 [p = 0.003]; 10 mg, -2.09 [p = 0.0002]). Greater improvements on the Clinician’s Interview-Based Impression of Change–plus version were observed with both donepezil groups than with the placebo group (overall donepezil treatment vs placebo p = 0.008); 25% of the placebo group showed improvement compared with 39% (p = 0.004) of the 5 mg group and 32% (p = 0.047) of the 10 mg group. Withdrawal rates due to adverse events were low (placebo, 8.8%; donepezil 5 mg, 10.1%; 10 mg, 16.3%).
Conclusions: Donepezil-treated patients demonstrated significant improvements in cognition and global function compared with placebo-treated patients, and donepezil was well tolerated.

Item Type: Article
ISSNs: 0028-3878 (print)
Related URLs:
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
R Medicine > RM Therapeutics. Pharmacology
ePrint ID: 40737
Date :
Date Event
August 2003Published
Date Deposited: 07 Jul 2006
Last Modified: 16 Apr 2017 21:51
Further Information:Google Scholar

Actions (login required)

View Item View Item